الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>MS023 dihydrochloride

MS023 dihydrochloride

رقم الكتالوجGC36655

MS023 ثنائي هيدروكلوريد هو مثبط فعال وانتقائي وخلوي لمثبط بروتين أرجينين ميثيل ترانسفيرازات (PRMTs) من النوع الأول البشري ، مع IC50s من 30 و 119 و 83 و 4 و 5 نانومتر لـ PRMT1 و PRMT3 و PRMT4 و PRMT6 و PRMT8 ، على التوالى.

Products are for research use only. Not for human use. We do not sell to patients.

MS023 dihydrochloride التركيب الكيميائي

Cas No.: 1992047-64-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
73٫00
متوفر
2mg
70٫00
متوفر
5mg
93٫00
متوفر
10mg
167٫00
متوفر
25mg
306٫00
متوفر
50mg
565٫00
متوفر
100mg
1020٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MS023 dihydrochloride is a potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively[1]. IC50: 30 nM (PRMT1), 119 nM (PRMT3), 83 nM (PRMT4), 4 nM (PRMT6), 5 nM (PRMT8)[1]

MS023 (1-1000 nM; 48 hours) inhibits PRMT1 methyltransferase activity in MCF7 cells[1]. MS023(1-1000 nM; 20 hours) inhibits PRMT6 methyltransferase activity in HEK293 cells[1]. Western Blot Analysis[1] Cell Line: MCF7 and HEK293 cells

[1]. Eram MS, et al. A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. ACS Chem Biol. 2016 Mar 18;11(3):772-81.

مراجعات

Review for MS023 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MS023 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.